Deutsche Bank
KROS icon

Deutsche Bank’s Keros Therapeutics KROS Stock Holding History

Deutsche Bank’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$501K Sell
46,802
-3,963
-8% -$44.1K ﹤0.01% 2774
2026
Q1 		$560K Sell
50,765
-144,516
-74% -$2.23M ﹤0.01% 2516
2025
Q4 		$3.98M Buy
195,281
+172,022
+740% +$3.02M ﹤0.01% 1416
2025
Q3 		$368K Sell
23,259
-188,378
-89% -$2.78M ﹤0.01% 2710
2025
Q2 		$2.83M Buy
211,637
+188,675
+822% +$2.55M ﹤0.01% 1511
2025
Q1 		$234K Sell
22,962
-3,995
-15% -$46.4K ﹤0.01% 2884
2024
Q4 		$427K Buy
26,957
+8,447
+46% +$439K ﹤0.01% 2696
2024
Q3 		$1.07M Sell
18,510
-105,603
-85% -$5.22M ﹤0.01% 2075
2024
Q2 		$5.67M Buy
124,113
+41
+0% +$2.2K ﹤0.01% 1201
2024
Q1 		$8.21M Sell
124,072
-234,204
-65% -$13.9M ﹤0.01% 1094
2023
Q4 		$14.2M Buy
358,276
+345,704
+2,750% +$10.8M 0.01% 888
2023
Q3 		$401K Sell
12,572
-70,319
-85% -$2.63M ﹤0.01% 2309
2023
Q2 		$3.33M Sell
82,891
-4,505
-5% -$197K ﹤0.01% 1399
2023
Q1 		$3.73M Buy
87,396
+75,946
+663% +$3.84M ﹤0.01% 1358
2022
Q4 		$550K Buy
11,450
+3,406
+42% +$159K ﹤0.01% 2396
2022
Q3 		$303K Sell
8,044
-2,231
-22% -$77.3K ﹤0.01% 2684
2022
Q2 		$285K Buy
10,275
+135
+1% +$5.92K ﹤0.01% 2951
2022
Q1 		$552K Sell
10,140
-1,006
-9% -$51.6K ﹤0.01% 2688
2021
Q4 		$652K Buy
11,146
+369
+3% +$18.4K ﹤0.01% 2675
2021
Q3 		$427K Sell
10,777
-287
-3% -$10.2K ﹤0.01% 3150
2021
Q2 		$469K Buy
11,064
+1,412
+15% +$76.5K ﹤0.01% 3264
2021
Q1 		$593K Sell
9,652
-792
-8% -$50.2K ﹤0.01% 2997
2020
Q4 		$736K Buy
10,444
+6,592
+171% +$415K ﹤0.01% 2655
2020
Q3 		$149K Buy
3,852
+336
+10% +$13.3K ﹤0.01% 3366
2020
Q2 		$132K Buy
+3,516
New +$108K ﹤0.01% 3322

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Deutsche Bank's KROS Position: Q2 2026 in Review

Deutsche Bank reduced its Keros Therapeutics (KROS) stake by 7.8% in Q2 2026, selling an estimated $44.1K and leaving 46,802 shares worth $501K. The position accounts for ﹤0.01% of the portfolio, ranked #2774.

Deutsche Bank first reported a position in KROS in Q2 2020 and has held it in 25 quarters since. The position peaked at $14.2M in Q4 2023. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Deutsche Bank held 46,802 shares of Keros Therapeutics worth $501K as of Q2 2026.
  • Deutsche Bank sold 3,963 Keros Therapeutics shares in Q2 2026, an estimated $44.1K.
  • Keros Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #2774 holding.
  • Deutsche Bank first reported a position in Keros Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Deutsche Bank's Keros Therapeutics position peaked at $14.2M in Q4 2023.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.